However, long-term efficacy is limited by disease progression in the brain due to inadequate pharmacokinetics (PK) and pharmacodynamics (PD).346,347 Researchers are working on enhancing the intrinsic properties of drugs, such as their PK and PD, to increase the effectiveness of RAS/RAF/MAPK inhibitors. The gene discussed is RAF1; the disease is Parkinson disease.